Alcon Nevanac approval
Executive Summary
Alcon's Nevanac (nepafenac ophthalmic suspension 0.1%) clears FDA Aug. 19 after a priority review for treatment of pain and inflammation associated with cataract surgery. Nepafenac, a new molecular entity and the first ophthalmic non-steroidal anti-inflammatory prodrug, converts intraocularly to the NSAID amfenac. Nevanac is administered to the eye three times daily beginning one day prior to cataract surgery and continuing through two weeks post-surgery, labeling states...